Aspire Biopharma Holdings (ASBP) Assets Average (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has 5 years of Assets Average data on file, last reported at $4.2 million in Q1 2026.

• On a quarterly basis, Assets Average rose 298.83% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 298.83% increase from a year earlier, with the FY2025 full-year figure at $730077.5, down 92.75% from the prior year.
• Assets Average for Q1 2026 stood at $4.2 million, up from $1.9 million in the prior quarter.
• Over the last five years, Assets Average for ASBP reached as high as $301.6 million in Q1 2023 and fell as low as $1.1 million in Q1 2025.
• Historically, Assets Average has averaged $105.9 million across 5 years, with a median of $20.1 million in 2024.
• Across the five-year window, Assets Average tumbled 94.74% in 2025 and soared 298.83% in 2026, its largest moves.
• Year by year, Assets Average stood at $299.0 million in 2022, then sank by 93.33% to $19.9 million in 2023, then plunged by 32.12% to $13.5 million in 2024, then plunged by 86.27% to $1.9 million in 2025, then jumped by 126.88% to $4.2 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $4.2 million in Q1 2026, $1.9 million in Q4 2025, and $1.7 million in Q3 2025.